Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Amino Acids

All Drugs and Chemicals

Arginine

arginine deiminase formulated with polyethlene glycol

ADI-PEG 20

Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that have arginine. In this study, the primary efficacy variable will be assessment of tumor response rate.

PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

Phase 2 Study of ADI PEG 20 in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

Determined by response criteria for cutaneous and non-cutaneous malignant lymphoma

Progression free survival - time from start of therapy until proven progression or death Overall survival Time on treatment Disease control rate Determine the pharmacodynamics of ADI-PEG 20 Determine the immunogenicity of ADI-PEG 20

Polaris Group

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia

* Time on treatment
* Overall survival
* Evaluate the response rate and correlate with patient disease burden, and type of disease.
* Determine the pharmacodynamics of ADI-PEG 20
* Determine the immunogenicity of ADI-PEG 20

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy	NCT01910025	Non-Hodgkin's L...	ADI-PEG 20	20 Years -	Polaris Group
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy	NCT01910025	Non-Hodgkin's L...	ADI-PEG 20	20 Years -	Polaris Group
PH 2 ADI-PEG 20 Acute Myeloid Leukemia	NCT01910012	Acute Myeloid L...	ADI-PEG 20	18 Years -	Polaris Group

Spots Global Cancer Trial Database for failed prior systemic therapy